TEL AVIV, Israel, March 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, March 15 at 8:30am Eastern Time to report fiscal year ended December 31, 2017 financial results.
| Thursday, March 15th @ 8:30am Eastern Time | ||
| Domestic: | 877-222-6394 | |
| International: | 703-925-2702 | |
| Conference ID: | 7392936 | |
| Webcast: | https://edge.media-server.com/m6/p/y3srj89d | |
| Replays, Available through March 29th: | ||
| Domestic: | 855-859-2056 | |
| International: | 404-537-3406 | |
| Conference ID: | 7392936 | |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
MEDIA CONTACT:
Matt Middleman, M.D.
LifeSci Public Relations
matt@lifescipublicrelations.com
(646) 627-8384